Johnson & Johnson Applies For Emergency Use Authorization for Anti-COVID-19 Vaccine

Enlarge this image


A dose of the Pfizer COVID-19 vaccine in New York, 2020. Johnson & Johnson is the third vaccine candidate to apply for emergency use authorization from the FDA. The vaccine requires a single dose and doesn’t require ultra-cold temperatures for storage.





Mary Altaffer/AP



hide caption



toggle caption


Mary Altaffer/AP



Shots — Health News
Dr. Fauci On Vaccinations And Biden’s ‘Refreshing’ Approach To COVID-19


Coronavirus Updates
Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19


Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19





Listen

·
3:47





3:47



Toggle more options

• Download
  


• 
  Embed
  
  
  
  Embed
  
  
  
  <iframe src=https://www.npr.org/player/embed/961887796/962022234″ width=100% height=290″ frameborder=0″ scrolling=no title=NPR embedded audio player>
  
  
  


• 
  
  
  Transcript
  
  

«The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response, said Paul Stoffels, Johnson & Johnson vice chairman of the executive committee and chief scientific officer. «Eighty-five percent efficacy in preventing severe COVID-19 disease and prevention of COVID-19-related medical interventions will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19.

The FDA is expected to hold a public meeting of outside advisers within a few weeks. If the advisers favor the vaccine, a decision authorize its use could come very soon afterwards.